111 Capital’s Vaxcyte PCVX Stock Holding History

111 Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,991	Closed	-$357K	–	636
2025 Q2	$357K	Buy	+10,991	New	+$360K	0.06%	311

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

111 Capital's PCVX Position: Q3 2025 in Review

111 Capital sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 10,991 shares — an estimated $357K sold.

111 Capital first reported a position in PCVX in Q2 2025 and held it in 1 quarter. The position peaked at $357K in Q2 2025. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

111 Capital reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
111 Capital sold 10,991 Vaxcyte shares in Q3 2025, an estimated $357K.
111 Capital first reported a position in Vaxcyte in Q2 2025 and held it in 1 quarter.
111 Capital's Vaxcyte position peaked at $357K in Q2 2025.
285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.